跳至主要内容
临床试验/NCT03635827
NCT03635827Unknown2 期

A Double-Blind, Randomized, Placebo-Controlled Trial of Xenon Inhalation for Treatment of Patients With Posttraumatic Stress Disorder

Nobilis Therapeutics Inc.0 个研究点目标入组 190 人开始时间: 2021年6月最近更新:
适应症

试验速览

阶段
2 期
入组人数
190
主要终点
CAPS-5

研究概览

简要总结

This study is a double-blind, randomized, placebo-controlled, clinical trial in parallel groups in patients with PTSD.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with a current diagnosis of PTSD (documented diagnosis of PTSD based on Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition [DSM-5] criteria and a Clinician Administered PTSD Scale [CAPS-5] total severity score of >30).
  • Male and female patients between the ages of 18 and 85 years.

排除标准

  • History of schizophrenia, bipolar and other psychotic disorders.
  • Patients with underlying pulmonary disease, chronic obstructive pulmonary disease (COPD), asthma or any other respiratory conditions / diseases that may affect the respiratory function.
  • Currently undergoing PTSD-targeted psychotherapy.
  • Currently undergoing exposure-based psychotherapy for any condition.

结局指标

主要结局

CAPS-5

时间窗: Baseline to Week 6

Change in CAPS-5 score

次要结局

  • PCL-5(Baseline to Week 6)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验